MFN2 sirna

MFN2 siRNA (Mouse)

Cat. Num. AAA8228747

• Gene Names: Mfn2; Fzo; D630023P19Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MFN2; MFN2 siRNA (Mouse); KIAA0214; MARF; Mitofusin-2; Hypertension-related protein 1; Mitochondrial assembly regulatory factor; HSG protein; Transmembrane GTPase MFN2; MFN2 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: MFN2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 757

• Applicable Applications for MFN2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse MFN2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MFN2 sirna

siRNA to inhibit MFN2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 553727138
• NCBI GeneID: 170731
• NCBI Accession #: NP_001272849.1
• NCBI GenBank Nucleotide #: NM_001285920.1
• UniProt Accession #: Q80U63; Q3V3B8; Q80WP4; Q80XK3; Q8BHF0; Q8BKV5; Q8R535; Q923X2; A2A7Y7; A8Y5E4
• Molecular Weight: 68,938 Da
• NCBI Official Full Name: mitofusin-2
• NCBI Official Synonym Full Names: mitofusin 2
• NCBI Official Symbol: Mfn2
• NCBI Official Synonym Symbols: Fzo; D630023P19Rik
• NCBI Protein Information: mitofusin-2
• UniProt Protein Name: Mitofusin-2
• Protein Family: Mitofusin
• UniProt Gene Name: Mfn2
• UniProt Synonym Gene Names: Kiaa0214; Marf; HSG protein
• UniProt Entry Name: MFN2_MOUSE

Uniprot Description

MFN2: Essential transmembrane GTPase, which mediates mitochondrial fusion. Fusion of mitochondria occurs in many cell types and constitutes an important step in mitochondria morphology, which is balanced between fusion and fission. MFN2 acts independently of the cytoskeleton. It therefore plays a central role in mitochondrial metabolism and may be associated with obesity and/or apoptosis processes. Overexpression induces the formation of mitochondrial networks. Plays an important role in the regulation of vascular smooth muscle cell proliferation. Defects in MFN2 are the cause of Charcot-Marie-Tooth disease type 2A2 (CMT2A2). CMT2A2 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. Defects in MFN2 are the cause of Charcot-Marie-Tooth disease type 6 (CMT6); also referred to as autosomal dominant hereditary motor and sensory neuropathy VI (HMSN6). CMT6 is an autosomal dominant form of axonal CMT associated with optic atrophy. Belongs to the mitofusin family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Hydrolase; Cytoskeletal; Membrane protein, integral; Membrane protein, multi-pass; Mitochondrial; EC 3.6.5.-; Cell cycle regulation

Cellular Component: microtubule cytoskeleton; mitochondrial outer membrane; membrane; mitochondrion; integral to membrane; cytosol; intrinsic to mitochondrial outer membrane

Molecular Function: GTPase activity; GTPase binding; protein binding; GTP binding; hydrolase activity; ubiquitin protein ligase binding; nucleotide binding

Biological Process: camera-type eye morphogenesis; mitochondrial fusion; negative regulation of smooth muscle cell proliferation; apoptosis; multicellular organismal development; mitochondrial membrane organization and biogenesis; autophagy; negative regulation of Ras protein signal transduction; blastocyst formation; mitochondrion localization; protein targeting to mitochondrion; response to unfolded protein